- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.03. | Bloomberg Terminal vs. Eikon: Analyzing Financial Data Tools | 1 | Investopedia | ||
| 02.03. | Eikon Therapeutics: Aktie steigt um 6 % nach positiven Analysten-Voten | 2 | Investing.com Deutsch | ||
| 02.03. | BofA initiates Eikon Therapeutics stock with buy rating on platform potential | 3 | Investing.com | ||
| 02.03. | Mizuho initiates Eikon Therapeutics stock coverage with outperform | 2 | Investing.com | ||
| 02.03. | Morgan Stanley initiates Eikon Therapeutics stock coverage at overweight | 4 | Investing.com | ||
| 02.03. | JPMorgan startet Coverage für Eikon Therapeutics mit "Overweight" | 2 | Investing.com Deutsch | ||
| EIKON THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 02.03. | Morgan Stanley sieht bei Eikon Therapeutics erhebliches Kurspotenzial | 5 | Investing.com Deutsch | ||
| 02.03. | JPMorgan initiates Eikon Therapeutics stock at Overweight | 1 | Investing.com | ||
| 26.02. | Eikon Therapeutics: Aktie fällt nach Herabstufung durch Wedbush | 4 | Investing.com Deutsch | ||
| 06.02. | Eikon Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 06.02. | Eikon Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 05.02. | Eikon Therapeutics Continues the IPO Parade, Raising $381M for Cancer Drug Clinical Trials | 1 | MedCity News | ||
| 05.02. | Immuno-responsive cancer biotech Eikon Therapeutics prices upsized IPO at $18 high end | 1 | Renaissance Capital | ||
| 05.02. | Eikon's upsized $381M Nasdaq listing marks largest biotech IPO since 2024 | 2 | FierceBiotech | ||
| 05.02. | Eikon, Veradermics close IPOs, as Salspera joins queue | 1 | pharmaphorum | ||
| 05.02. | Eikon Therapeutics prices upsized IPO of 21.18M shares at $18.00 | 1 | Seeking Alpha | ||
| 05.02. | Eikon Therapeutics nets a $381M IPO amid burst of biotech offerings | 1 | BioPharma Dive | ||
| 05.02. | Eikon Therapeutics, Inc.: Eikon Therapeutics Announces Pricing of Upsized Initial Public Offering | 165 | GlobeNewswire (Europe) | MILLBRAE, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. ("Eikon"), a late-stage clinical biopharmaceutical company dedicated to developing important, innovative medicines to address... ► Artikel lesen | |
| 29.01. | Merck reportedly eyeing $30M stake in Eikon Therapeutics' IPO | 22 | Seeking Alpha | ||
| 28.01. | Eikon sets $274M goal for upcoming stock market debut | 1 | FierceBiotech |
1 2 Weiter >>
30 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ERASCA | 14,600 | -4,32 % | Erasca (ERAS) Adds 13%; Soars 310% YTD | ||
| MONTE ROSA THERAPEUTICS | 15,630 | -2,68 % | Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates | Positive interim Phase 1 data of NEK7-directed MGD MRT-8102 demonstrated profound CRP reductions in elevated CVD-risk subjects; readout of expanded part 3 CRP PoC trial (now called GFORCE-1) anticipated... ► Artikel lesen | |
| IMMUNOVANT | 22,980 | -2,83 % | Bernstein initiates Immunovant stock coverage with neutral rating | ||
| KYMERA THERAPEUTICS | 77,91 | -2,06 % | Kymera Therapeutics (KYMR) to Present Phase 1b BroADen Trial Data for KT-621 at AAD 2026 | ||
| NURIX THERAPEUTICS | 14,430 | -3,25 % | Nurix Therapeutics, Inc.: Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides a Corporate Update | First patients dosed in DAYBreak registrational program for bexobrutideg in relapsed/refractory CLLPresented Phase 1 results at ASH 2025 that support bexobrutideg's potential best-in-class profile... ► Artikel lesen | |
| INHIBRX BIOSCIENCES | 60,92 | -4,72 % | Inhibrx Biosciences, Inc.: Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial Results | SAN DIEGO, March 19, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the fourth... ► Artikel lesen | |
| QIAGEN | 34,805 | -1,28 % | Qiagen unter Druck, Zalando auf Erholungskurs: DAX-Ausblick | Der DAX befindet sich weiter auf Talfahrt. In der abgelaufenen Woche büßte das größte deutsche Börsenbarometer rund 144 Punkte ein und schloss -0,61% niedriger mit 23.447 Punkten. Die höchsten Verluste... ► Artikel lesen | |
| PHATHOM PHARMACEUTICALS | 11,210 | +0,54 % | Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results | FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal... ► Artikel lesen | |
| ARS PHARMACEUTICALS | 8,170 | -0,85 % | ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy (epinephrine nasal spray) Commercialization | neffy delivers $72.2 million of U.S. net product revenue in first full year Intranasal epinephrine platform advances with Phase 2b CSU data expected mid-2026 Strong balance sheet of $245.0 million... ► Artikel lesen | |
| SPYGLASS PHARMA | 26,000 | +1,13 % | SpyGlass Pharma, Inc.: SpyGlass Pharma Announces Positive Topline 12-Month Phase 1/2 Trial Results for Its Innovative BIM-IOL System | 97% of patients who received the BIM-IOL System off all topical IOP-lowering therapy at 12-months100% of BIM-IOL System patients achieved 20/32 or better BCDVA and a mean BCDVA equivalent to 20/20... ► Artikel lesen | |
| IMMIX BIOPHARMA | 9,110 | -5,89 % | Artificial Intelligence Technology Solutions, Inc.: AITX's RAD Confirms Immix, AWS, and Circadian Risk Participation at ISC West 2026 | Detroit, Michigan--(Newsfile Corp. - February 12, 2026) - Artificial Intelligence Technology Solutions, Inc. (OTCID: AITX) (the "Company"), a global leader in AI-driven security and productivity... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 46,080 | +0,96 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Portfolio Execution | - ARCALYST- (rilonacept) Q4 2025 and full year 2025 net product revenue of $202.1 million and $677.6 million, respectively -- ARCALYST 2026 net product revenue expected to be $900 - $920 million... ► Artikel lesen | |
| LENZ THERAPEUTICS | 10,480 | -8,79 % | LENZ Therapeutics, Inc.: LENZ Therapeutics and Sarah Jessica Parker announce the launch of "Make it VIZZable", the VIZZ consumer campaign | Struggling to see up close? VIZZ is a revolutionary, once-daily eye drop and alternative to reading glasses to restore near vision for up to 10 hours The "Make it VIZZable" campaign features SJP enjoying... ► Artikel lesen | |
| KYVERNA THERAPEUTICS | 7,940 | -7,08 % | Kyverna Therapeutics: Ein kommender Biotech-Star? | Die Aktie von Kyverna Therapeutics rückt zunehmend in den Blick von Investoren, die auf bahnbrechende CAR-T-Therapien im Autoimmunbereich setzen. Mit vielversprechenden Studiendaten und einer bevorstehenden... ► Artikel lesen | |
| SEPTERNA | 24,180 | 0,00 % | Septerna, Inc.: Septerna Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2025 Financial Results | Compelling Phase 1 Data for SEP-631 (MRGPRX2 NAM) in Healthy Volunteers Support Phase 2b Development, Initially in Chronic Spontaneous Urticaria (CSU) in Second Half of 2026 Advancing SEP-479 (PTH1R... ► Artikel lesen |
Das Unternehmen EIKON THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +7,25 % bei einem Aktienkurs von 11,840 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu EIKON THERAPEUTICS INC finden Sie auf Wallstreet Online.